诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09969 诺诚健华

已收盘 12-16 16:08:20

13.280

-0.270

-1.99%

最高13.510	最低12.830	成交量721.50万
今开13.450	昨收13.550	日振幅5.02%
总市值233.99亿	流通市值198.40亿	总股本17.62亿
成交额9,461万	换手率0.48%	流通股本14.94亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09969","market":"HK","secType":"STK","nameCN":"诺诚健华","latestPrice":13.28,"timestamp":1765872500011,"preClose":13.55,"halted":0,"volume":7215000,"delay":0,"floatShares":1494000000,"shares":1762000000,"eps":-0.287624241481251,"marketStatus":"已收盘","change":-0.27,"latestTime":"12-16 16:08:20","open":13.45,"high":13.51,"low":12.83,"amount":94607815,"amplitude":0.050185,"askPrice":13.28,"askSize":14000,"bidPrice":13.2,"bidSize":8000,"shortable":3,"etf":0,"ttmEps":-0.15763578428504746,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765935000000},"marketStatusCode":5,"adr":0,"listingDate":1584892800000,"exchange":"SEHK","adjPreClose":13.55,"openAndCloseTimeList":[[1765848600000,1765857600000],[1765861200000,1765872000000]],"volumeRatio":1.061732,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688428","market":"SH","secType":"STK","nameCN":"诺诚健华","latestPrice":22.5,"timestamp":1765868400000,"preClose":23.96,"halted":0,"volume":7546400,"delay":0,"premium":"-46.65"}},"requestUrl":"/m/hq/s/09969","defaultTab":"news","newsList":[{"id":"2591097566","title":"12月16日诺诚健华跌6.09%，富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2591097566","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591097566?lang=zh_cn&edition=full","pubTime":"2025-12-16 15:36","pubTimestamp":1765870568,"startTime":"0","endTime":"0","summary":"证券之星消息，12月16日诺诚健华跌6.09%，收盘报22.5元，换手率2.81%，成交量7.55万手，成交额1.72亿元。重仓诺诚健华的前十大公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共30家，其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为34.91亿元，最新净值3.1742，较上一交易日下跌3.71%，近一年上涨34.53%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121600020122.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688428","BK1574","BK1161","BK0239","09969"],"gpt_icon":0},{"id":"2591565672","title":"创新药概念再度走低 诺诚健华(09969.HK)跌超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591565672","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591565672?lang=zh_cn&edition=full","pubTime":"2025-12-16 11:21","pubTimestamp":1765855266,"startTime":"0","endTime":"0","summary":"每经AI快讯，创新药概念股再度走低，截至发稿，诺诚健华(09969.HK)跌5.09%，报12.86港元；石药集团(01093.HK)跌3.99%，报7.21港元；信达生物(01801.HK)跌3.36%，报79港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512163592831521.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512163592831521.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK1161","BK0239","688428","159992","09969","06978"],"gpt_icon":0},{"id":"2591644571","title":"诺诚健华：截至2025年11月28日A股股东户数约1.79万户","url":"https://stock-news.laohu8.com/highlight/detail?id=2591644571","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591644571?lang=zh_cn&edition=full","pubTime":"2025-12-15 21:43","pubTimestamp":1765806180,"startTime":"0","endTime":"0","summary":"证券日报网讯12月15日，诺诚健华在互动平台回答投资者提问时表示，截至2025年11月28日公司A股股东户数约为1.79万户。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512153592007823.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","159982","BK1161","BK1574","688428","09969","399300"],"gpt_icon":0},{"id":"2591620772","title":"每日卖空追踪 | 诺诚健华 12月15日卖空量成交41.9万股，卖空比例为5.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591620772","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591620772?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:30","pubTimestamp":1765787441,"startTime":"0","endTime":"0","summary":"诺诚健华北京时间12月15日，跌5.05%，卖空量成交41.9万股，较上一交易日减少72.79%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215163649a44d43e5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215163649a44d43e5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","09969","BK1161"],"gpt_icon":0},{"id":"2591665068","title":"诺诚健华(688428.SH)：奥布替尼治疗系统性红斑狼疮IIb期研究达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2591665068","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591665068?lang=zh_cn&edition=full","pubTime":"2025-12-14 16:27","pubTimestamp":1765700828,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华(688428.SH)公告，公司自主研发的BTK抑制剂奥布替尼治疗系统性红斑狼疮(简称“SLE”)的IIb期临床研究达到主要终点，并获国家药品监督管理局(NMPA)药品审评中心(CDE)批准开展III期注册性临床试验。公司将尽快启动该临床研究。临床IIb结果展示，在接受治疗48周的患者中，奥布替尼展现了卓越的有效性、良好的耐受性和安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381246.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688428","BK0239","BK1574","09969","BK1161"],"gpt_icon":0},{"id":"2590257886","title":"港股诺诚健华涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590257886","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590257886?lang=zh_cn&edition=full","pubTime":"2025-12-12 14:21","pubTimestamp":1765520510,"startTime":"0","endTime":"0","summary":"每经AI快讯，诺诚健华(09969.HK)涨超3%，截至发稿，涨3.24%，报14港元，成交额5105.45万港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512123590068918.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512123590068918.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","09969","BK0239","BK1161","688428"],"gpt_icon":0},{"id":"2591687883","title":"近期，齐鲁制药、诺诚健华等在抗肿瘤药方面好消息频现！","url":"https://stock-news.laohu8.com/highlight/detail?id=2591687883","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591687883?lang=zh_cn&edition=full","pubTime":"2025-12-12 14:11","pubTimestamp":1765519893,"startTime":"0","endTime":"0","summary":"近些年来，中国抗肿瘤药物市场销售一直呈现稳步增长趋势。随着老龄化及公众癌症预防意识的持续提高，抗肿瘤药物市场规模还在不断上涨，业内预计到2029年，中国抗肿瘤药物行业市场规模有望达到5590亿元。近期，就有不少药企在新药临床、上市方面传来好消息。其通过瘤内注射，具有抑制肿瘤生长的功能。总的来说，2025年中国在抗肿瘤药方面的不断突破，是近年来医药行业转型升级的集中体现。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212141533a44414c0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212141533a44414c0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09969","BK1574","BK1161","BK1191","01477"],"gpt_icon":0},{"id":"2590520907","title":"港股异动 | 诺诚健华(09969)涨超3% 预计不久将递交佐来曲替尼治疗儿童患者新药上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2590520907","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590520907?lang=zh_cn&edition=full","pubTime":"2025-12-12 14:05","pubTimestamp":1765519550,"startTime":"0","endTime":"0","summary":"消息面上，12月11日，诺诚健发布公告，国家药品监督管理局已批准第二代小分子泛原肌球蛋白相关激酶抑制剂佐来曲替尼，用于治疗携带NTRK融合基因的成人和12岁以上青少年实体瘤患者。佐来曲替尼已被NMPA纳入“星光计划”，该计划是一项为鼓励儿童抗肿瘤药物研发而开展的试点项目。本公司预计不久将递交佐来曲替尼治疗儿童患者的新药上市申请。NTRK融合基因存在于各种类型的肿瘤，目前已在超过26种实体瘤中发现了NTRK融合基因。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380803.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1574","688428","09969","BK0239","BK1161"],"gpt_icon":0},{"id":"2590475925","title":"港股早知道 | 国际银价续创新高；汇丰：预计美联储明后两年不会降息；云顶新耀与海森生物达成战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2590475925","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590475925?lang=zh_cn&edition=full","pubTime":"2025-12-12 09:00","pubTimestamp":1765501238,"startTime":"0","endTime":"0","summary":"此前美联储政策制定者以分化的表决结果将利率下调了25个基点。云顶新耀宣布与海森生物达成战略合作，发挥商业化平台的优势与布局2025年12月11日，港股创新药企云顶新耀宣布，其全资附属公司云顶新耀医药科技有限公司已与海森生物医药有限公司签署两项战略合作协议：商业化服务协议以及授权许可协议。本次增持后，朱江明及傅利泉与所属的单一最大股东集团合共持有公司2.09亿股H股及1.29亿股内资股，占公司已发行总股数的23.75%。","market":"us","thumbnail":"https://static.tigerbbs.com/38508134c6853c521e764dc952e7334a","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/38508134c6853c521e764dc952e7334a"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380662.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BZ08YT58.USD","06099","BK1147","09969","BK1583","HK0000165453.HKD","BK1515","IE00BZ08YR35.GBP","BK1521","01952","02670","01177","09863","BK1161","BK1183","BK1574","BK1119","IE00BZ08YS42.EUR","BK1564","BK1589","BK1191"],"gpt_icon":0},{"id":"2590359020","title":"每日卖空追踪 | 诺诚健华 12月11日卖空量成交22万股，卖空比例为6.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590359020","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590359020?lang=zh_cn&edition=full","pubTime":"2025-12-11 16:30","pubTimestamp":1765441840,"startTime":"0","endTime":"0","summary":"诺诚健华北京时间12月11日，涨0.15%，卖空量成交22万股，较上一交易日减少77.62%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211163756979c69b4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211163756979c69b4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09969","BK1574","BK1161"],"gpt_icon":0},{"id":"2590902245","title":"诺诚健华12月11日获主力加仓77.4万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2590902245","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590902245?lang=zh_cn&edition=full","pubTime":"2025-12-11 16:16","pubTimestamp":1765440962,"startTime":"0","endTime":"0","summary":"12月11日, 诺诚健华股价涨0.15%，报收13.58元，成交金额4591.1万元，换手率0.23%，振幅3.39%，量比0.60。诺诚健华今日主力资金净流入77.4万元，上一交易日主力净流入352.7万元。该股近5个交易日下跌5.89%，主力资金累计净流入291.3万元；近20日主力资金累计净流入2710.5万元，其中净流入天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211162248a6990daf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211162248a6990daf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09969","BK1574"],"gpt_icon":0},{"id":"2590560665","title":"国产创新药多点突破，抢滩1000亿美元规模炎症性肠病药物市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2590560665","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590560665?lang=zh_cn&edition=full","pubTime":"2025-12-11 11:25","pubTimestamp":1765423552,"startTime":"0","endTime":"0","summary":"有数据预测，到2032年全球IBD市场将达到1000亿美元规模。如云顶新耀引进的S1P调节剂伊曲莫德已在国内申报上市。资料显示，伊曲莫德作为一种新一代高选择性S1P受体调节剂，通过与S1P受体1、4和5结合，发挥调节免疫和炎症的作用。此外，匹康奇拜单抗200 mg组和600mg组达到症状缓解、内镜缓解或黏膜愈合的受试者比例均高于安慰剂组。目前评估Hemay005用于中度至重度溃疡性结肠炎的有效性的一项临床II期研究正在进行中。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211112914a7311dcb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211112914a7311dcb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2097828474.EUR","LU2097828714.EUR","BK1589","LU2328871848.SGD","LU2097828631.EUR","BK1161","09969","06978","01801","LU2488822045.USD","LU1969619763.USD","BK1574","LU0455707207.USD","HK0000165453.HKD","LU0502904849.HKD","LU2097828557.USD","LU2242644610.SGD","BK1583","LU2097828805.USD"],"gpt_icon":0},{"id":"2590105213","title":"每日卖空追踪 | 诺诚健华 12月09日卖空量成交26.6万股，卖空比例为2.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590105213","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590105213?lang=zh_cn&edition=full","pubTime":"2025-12-09 16:30","pubTimestamp":1765269041,"startTime":"0","endTime":"0","summary":"诺诚健华北京时间12月09日，跌3.99%，卖空量成交26.6万股，较上一交易日减少61.05%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209163658979827b5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209163658979827b5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09969","BK1161","BK1574"],"gpt_icon":0},{"id":"2590031058","title":"诺诚健华12月09日主力净流出1300.9万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2590031058","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590031058?lang=zh_cn&edition=full","pubTime":"2025-12-09 16:15","pubTimestamp":1765268127,"startTime":"0","endTime":"0","summary":"12月09日, 诺诚健华股价跌3.99%，报收13.70元，成交金额1.4亿元，换手率0.69%，振幅6.59%，量比1.98。诺诚健华今日主力资金净流出1300.9万元，上一交易日主力净流入656.0万元。该股近5个交易日下跌3.59%，主力资金累计净流出275.8万元；近20日主力资金累计净流入2870.7万元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209161721a43d3551&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209161721a43d3551&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","09969","BK1161"],"gpt_icon":0},{"id":"2590510310","title":"诺诚健华新型BCL2抑制剂Mesutoclax最新临床数据闪耀第67届美国血液学会（ASH）年会","url":"https://stock-news.laohu8.com/highlight/detail?id=2590510310","media":"制药在线","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590510310?lang=zh_cn&edition=full","pubTime":"2025-12-09 11:00","pubTimestamp":1765249217,"startTime":"0","endTime":"0","summary":"2025年12月9日，生物医药高科技公司诺诚健华今天宣布，公司自主研发的新型BCL2抑制剂mesutoclax共有三项研究在第67届美国血液学会年会上进行了公布。Mesutoclax治疗复发/难治性MCL的研究入选口头报告，mesutoclax治疗CLL/SLL和AML的两项研究入选海报展示。无论在初治CLL/SLL还是复发/难治性 CLL/SLL患者中，125毫克mesutoclax剂量组的ORR均为100%。Mesutoclax单药或联合奥布替尼治疗都展现了良好的安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209110021a43ca5a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209110021a43ca5a8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09969","BK1574","BK1161"],"gpt_icon":0},{"id":"2590522953","title":"(演示专用)诺诚健华2025年第三季度营收3.84亿元，同比增长38.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590522953","media":"时代财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590522953?lang=zh_cn&edition=full","pubTime":"2025-12-08 16:44","pubTimestamp":1765183456,"startTime":"0","endTime":"0","summary":"时代财经AI快讯，11月13日，诺诚健华（688428.SH）发布公告，2025年第三季度营业收入3.84亿元，同比增长38.09%；归属于上市公司股东的净利润为-3432.35万元；基本每股收益为-0.02元/股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208164936a43b02df&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208164936a43b02df&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09969"],"gpt_icon":0},{"id":"2590352296","title":"每日卖空追踪 | 诺诚健华 12月08日卖空量成交27万股，卖空比例为5.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590352296","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590352296?lang=zh_cn&edition=full","pubTime":"2025-12-08 16:30","pubTimestamp":1765182640,"startTime":"0","endTime":"0","summary":"诺诚健华北京时间12月08日，跌0.63%，卖空量成交27万股，较上一交易日减少7.53%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208163651a43afc04&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208163651a43afc04&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","09969","BK1161"],"gpt_icon":0},{"id":"2590352262","title":"医保目录调整 为血液肿瘤患者提供可及用药支持","url":"https://stock-news.laohu8.com/highlight/detail?id=2590352262","media":"科技日报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590352262?lang=zh_cn&edition=full","pubTime":"2025-12-08 11:20","pubTimestamp":1765164050,"startTime":"0","endTime":"0","summary":"据了解，本次医保目录的新增药物覆盖淋巴瘤、白血病、多发性骨髓瘤等常见领域，这将进一步拓宽血液肿瘤患者保障边界、填补细分病种保障空白，切实减轻患者用药经济负担，为临床治疗提供更可及的用药支持。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208112628a72a23e4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208112628a72a23e4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09969","BK1574","BK1161"],"gpt_icon":0},{"id":"2589712808","title":"诺诚健华宣布宜诺凯（奥布替尼）新增适应症纳入2025年国家医保药品目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589712808","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589712808?lang=zh_cn&edition=full","pubTime":"2025-12-07 18:07","pubTimestamp":1765102044,"startTime":"0","endTime":"0","summary":"12月7日，2025年《国家基本医疗保险、生育保险和工伤保险药品目录》（国家医保药品目录）在广州正式公布。诺诚健华医药有限公司（以下简称“诺诚健华”）自主研发的布鲁顿酪氨酸激酶（BTK）抑制剂宜诺凯?（奥布替尼）新增适应症被纳入2025年国家医保药品目录，用于一线治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512073584604256.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK0239","BK1161","688428","09969"],"gpt_icon":0},{"id":"2588880472","title":"诺诚健华（688428）披露证券变动月报表，12月04日股价上涨1.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588880472","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588880472?lang=zh_cn&edition=full","pubTime":"2025-12-04 22:20","pubTimestamp":1764858034,"startTime":"0","endTime":"0","summary":"截至2025年12月4日收盘，诺诚健华报收于24.84元，较前一交易日上涨1.89%，最新总市值为438.34亿元。公司近日发布公告，披露截至2025年11月30日的证券变动月报表。公告显示，诺诚健华医药有限公司法定股本无变动，已发行股份总数保持不变。公司存在股权激励计划，包括2023年及2024年人民币股股份激励计划，部分限制性股票已失效，但本月未发生新股发行或库存股转让。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120400039635.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","688428","BK1574","161027","09969","BK0239"],"gpt_icon":0}],"profile":{"websiteUrl":"https://cn.innocarepharma.com","stockEarnings":[{"period":"1week","weight":-0.0505},{"period":"1month","weight":-0.1068},{"period":"3month","weight":-0.2099},{"period":"6month","weight":0.0203},{"period":"1year","weight":1.1961},{"period":"ytd","weight":1.2141}],"compareEarnings":[{"period":"1week","weight":-0.0053},{"period":"1month","weight":-0.0533},{"period":"3month","weight":-0.0306},{"period":"6month","weight":0.0809},{"period":"1year","weight":0.2833},{"period":"ytd","weight":0.2776}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"诺诚健华医药有限公司是一家主要从事生物医药研发、生产和商业化的中国公司。该公司专注于肿瘤和自身免疫性疾病等存在巨大未满足临床需求的领域。该公司的主要产品管线包括奥布替尼、Tafasitamab、ICP-490、ICP-B02、ICP-248、ICP-B05、ICP-332、ICP-488、ICP-192、ICP-723、ICP-033和ICP-189等。其产品主要用于治疗血液瘤、实体瘤和自身免疫病。该公司还在开发用于治疗由B细胞或T细胞功能异常所导致的自身免疫性疾病的产品。该公司主要在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.115368},{"month":2,"riseRate":0.6,"avgChangeRate":0.148393},{"month":3,"riseRate":0,"avgChangeRate":-0.036551},{"month":4,"riseRate":0.666667,"avgChangeRate":0.116223},{"month":5,"riseRate":0.166667,"avgChangeRate":-0.042592},{"month":6,"riseRate":0.833333,"avgChangeRate":0.12939},{"month":7,"riseRate":0.5,"avgChangeRate":0.039258},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.082108},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.024907},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.033299},{"month":11,"riseRate":0.833333,"avgChangeRate":0.100833},{"month":12,"riseRate":0.5,"avgChangeRate":0.001413}],"exchange":"SEHK","name":"诺诚健华","nameEN":"INNOCARE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺诚健华(09969)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺诚健华,09969,诺诚健华股票,诺诚健华股票老虎,诺诚健华股票老虎国际,诺诚健华行情,诺诚健华股票行情,诺诚健华股价,诺诚健华股市,诺诚健华股票价格,诺诚健华股票交易,诺诚健华股票购买,诺诚健华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺诚健华(09969)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}